Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 ...

Add Yahoo as a preferred source to see more of our stories on Google. Novo Nordisk won't add Alzheimer's disease to the list of conditions its blockbuster diabetes and weight-loss drugs, Ozempic and ...

The NHS spending watchdog must look again at its decision after drug manufacturers successfully appealed against Nice's ruling that the treatments were not cost-effective ...

A new pill for those genetically at risk for Alzheimer’s has shown benefits in clinical trials. FotografiaBasica/Getty Images One gene variant that is particularly associated with Alzheimer’s disease ...

In April, the future was looking bleak for an experimental Alzheimer's drug called valiltramiprosate, or ALZ-801. Researchers had just released topline results of a study of more than 300 people age ...

Eli Lilly and Eisai's battle to secure NHS reimbursement for their Alzheimer's disease therapies is dragging on, with guidance blocking use of the drug set for another review. After a successful ...

The U.K.’s national health spending watchdog will reevaluate its decision to exclude the use of two Alzheimer’s drugs ...

An experimental pill could slow memory loss and brain shrinkage in some Alzheimer’s patients, new research suggests. The pill, called ALZ-801 (valiltramiprosate), was shown to be effective in people ...